Articles by James Calloway
Gilead Hits 52-Week Peak on FDA Label Expansion for Yescarta, Earnings in Focus
Gilead Sciences reached a 52-week high after the FDA approved a label update for its Yescarta therapy, expanding use to a rare brain lymphoma. The stock's rally comes ahead of the company's quarterly earnings report.
Disney Shares Face Regulatory Scrutiny as FCC Probes ABC Talk Show
Walt Disney Co's stock will be monitored Monday after U.S. regulators launched an investigation into ABC's 'The View' regarding election airtime rules. Shares closed Friday at $108.70, up 3.6%.
Novo Nordisk Rebounds as FDA Vows Crackdown on Wegovy Copycats
Novo Nordisk B shares surged 5.29% after Hims & Hers halted its $49 compounded version of Wegovy, with the FDA pledging action against unauthorized copycats. The stock remains down roughly 20% over five sessions amid pricing uncertainty.
Inditex Initiates Share Repurchase Ahead of March Earnings
Inditex shares edged higher Friday after announcing a €180 million buyback program for employee incentives, with full-year results due March 11.
Thermo Fisher Shares End Week Lower Amid Research Funding Concerns
Thermo Fisher Scientific closed Friday at $542.83, down 6.7% for the week as investors weigh pressure from academic research funding cuts. The company's 2026 outlook projects adjusted earnings of $24.22 to $24.80 per share.
T-Mobile Shares Decline Ahead of Key Earnings and Strategy Update
T-Mobile US stock fell 2.2% on Friday, underperforming the broader market and telecom peers as investors await the company's quarterly results and capital markets day presentation on February 11.
China Mobile Faces VAT Hike Impact as Inflation Data and Earnings Loom
China Mobile's A-shares trade near 95 yuan as a VAT increase on telecom services pressures profits. Investors await February inflation figures and the company's March earnings report.
L'Oréal Shares Dip Ahead of Annual Results; China Demand, Margins in Focus
L'Oréal shares closed slightly lower ahead of its 2025 annual results release. Analysts anticipate sales near €44.1 billion, with investor attention on guidance and Chinese market performance.
